Worth Watching Stocks: Endo International plc (NASDAQ:ENDP), Juno Therapeutics Inc. (NASDAQ:JUNO)

stock updates

Endo International plc (NASDAQ:ENDP)

The company announced its last quarter financial performance results on 11/08/2016. Endo International plc (NASDAQ:ENDP) belongs to Medical sector that declined -4.97% in value when last trading session closed at $16.25. The company has a market capitalization of $3.61 Billion. The company’s stock has a Return on Assets (ROA) of -0.7 percent, a Return on Equity (ROE) of -2.1 percent and Return on Investment (ROI) of 0.9 percent. The company reached its 52-Week high of $63.71 on Dec 7, 2015 and 52-Week low of $12.56 on May 12, 2016.

Earnings per share (ttm) for Endo International plc (NASDAQ:ENDP) according to Finviz Data is $2.47.

The growth estimate for Endo International plc (NASDAQ:ENDP) for the current quarter is 22.8 percent. The projected growth estimate for the next quarter is 30.6 percent. The company’s stock has grown by -3.06 percent in the past 5 years. For the next 5 years, the company is expected to grow by 0.41 percent.

This company was Upgrade by Susquehanna on 10-Nov-16  to Positive.

The 21 analysts offering 12-month price forecasts for Endo International PLC have a median target of 25.00, with a high estimate of 35.00 and a low estimate of 15.00. The median estimate represents a +53.85% increase from the last price of 16.25.

Financial History for Endo International plc (NASDAQ:ENDP):

Following Earnings result, share price were UP 15 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 91% percent of times. It has met expectations  0 times and missed earnings  1 times.

The consensus recommendation for Endo International plc (NASDAQ:ENDP) is 2. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 2.12. In comparison, the consensus recommendation 60 days ago was at 2.31, and 90 days ago was at 2.31 respectively.

Future Expectations for Endo International plc (NASDAQ:ENDP):

When the current quarter ends, Wall Street expects Endo International plc to have earnings per share of $1.67.

Revenue is expected to range from 1.1 Billion to 1.22 Billion with an average of 1.17 Billion.

Company Profile:

Endo International plc is a global specialty healthcare company. It develops, manufactures, markets, and distributes quality branded pharmaceutical and generic products as well as medical devices. Endo offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel for pain, urology, endocrinology, and oncology. The company also provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women’s health, and hypertension markets. Endo International plc, formerly known as Endo Pharmaceuticals Holdings Inc., is headquartered in Dublin, Ireland.

Juno Therapeutics Inc. (NASDAQ:JUNO):

Juno Therapeutics Inc. (NASDAQ:JUNO) belongs to Medical sector closed its last session with a loss of -4.96 percent and closed its previous trading session at $29.88. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $-2.81. The company has the Market capitalization of $3.24 Billion. The company’s stock has a Return on Assets (ROA) of -19 percent, a Return on Equity (ROE) of -24 percent and Return on Investment (ROI) of -20.3 percent. The company reached its 52-Week high of $57.82 on Dec 1, 2015 and 52-Week low of $22.37 on Feb 3, 2016.

This company was Downgrade by JP Morgan on 8-Jul-16 to Neutral.

The 12 analysts offering 12-month price forecasts for Juno Therapeutics Inc have a median target of 45.00, with a high estimate of 61.00 and a low estimate of 23.00. The median estimate represents a +50.60% increase from the last price of 29.88.

Financial History for Juno Therapeutics Inc. (NASDAQ:JUNO):

Following Earnings result, share price were UP 4 times out of last 7 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 25% percent of times. It has met expectations  2  times and missed earnings  4  times.

The consensus recommendation for Juno Therapeutics Inc. (NASDAQ:JUNO) is 1.9. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.78. In comparison, the consensus recommendation 60 days ago was at 1.63, and 90 days ago was at 1.63 respectively.

Future Expectations for Juno Therapeutics Inc. (NASDAQ:JUNO):

When the current quarter ends, Wall Street expects Juno Therapeutics Inc. to have earnings per share of $-0.62.

Revenue is expected to range from 7.5 Million to 20.3 Million with an average of 13.96 Million.

Company Profile:

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company develops cellular immunotherapies based on two platforms – Chimeric Antigen Receptors (CARs) and T Cell Receptors (TCRs) technologies. Its clinical CD19 product candidates include JCAR015 that is in Phase I clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL whose cancer has recurred after a bone marrow transplant; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies. Juno Therapeutics, Inc. is headquartered in Seattle, Washington.